Traditional cancer immunotherapies primarily focus on the adaptive immune system, using checkpoint inhibitors to unleash T-cells against tumors. However, many solid malignancies remain resistant to T-cell-mediated destruction. As reviewed by Ming Yi et al. in Exploiting innate immunity for cancer immunotherapy, a powerful alternative strategy involves mobilizing the innate immune system—specifically macrophages—by blocking the inhibitory "don't eat me" signals that tumors use to evade phagocytosis.
The Molecular Mechanism of Phagocytic Evasion
Macrophages are programmed to identify and engulf abnormal or damaged cells. To prevent the destruction of healthy tissue, this process is tightly regulated by surface proteins that act as myeloid checkpoints. Tumor cells frequently hijack these pathways by overexpressing inhibitory ligands, effectively rendering themselves invisible to innate immune surveillance.
The most prominent of these pathways is the CD47–SIRPα axis. As detailed by Pengfei Su et al. in Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review), malignant cells overexpress the surface glycoprotein CD47. When CD47 binds to Signal Regulatory Protein Alpha (SIRPα) on macrophages, it triggers an intracellular inhibitory cascade.
The structural intuition behind this "brake" relies on downstream enzymatic recruitment. Xiaofeng Niu et al. in 793 Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity note that the engagement of SIRPα recruits the tyrosine phosphatase SHP-1. Once activated, SHP-1 dephosphorylates proteins critical for initiating cytoskeletal rearrangement, effectively paralyzing the macrophage's ability to extend its membrane and engulf the tumor cell.
A parallel mechanism operates via the CD24–Siglec-10 axis. As highlighted by Jiawei Zhou et al. in Tumor-Associated Macrophages: Recent Insights and Therapies, tumor-expressed CD24 interacts with Siglec-10 on tumor-associated macrophages (TAMs) to deliver an analogous suppressive signal, providing tumors with multiple layers of protection against phagocytic clearance.
Therapeutic Strategies to Remove the Brake
To restore the phagocytic capacity of the innate immune system, therapeutic interventions aim to disrupt these molecular handshakes using targeted antibodies or genetic engineering.
Targeting the Ligand
One approach involves coating the tumor's "don't eat me" proteins to prevent them from reaching macrophage receptors. For example, Yanni Zhang et al. in 859 Combination of HER2 ADC and lemzoparlimab elicits enhanced efficacy in both HER2 high-and low-expressing breast and gastric cancers demonstrated that combining the anti-CD47 antibody lemzoparlimab with HER2-targeted antibody-drug conjugates (ADCs) creates a powerful synergy, driving macrophage clearance even in tumors with low target expression.
To avoid off-target toxicities—since CD47 and CD24 are also expressed on healthy cells—researchers are developing highly selective agents. Jun‐Li Liu et al. in 1364 Discovery of NXA01, a novel CD24 antibody with tumor selectivity and potent anti-tumor activity designed NXA01, an antibody that specifically targets the hypoglycosylated form of CD24 found predominantly on cancer cells, sparing healthy tissue from autoimmune attack.
Targeting the Receptor
Alternatively, therapies can block the macrophage side of the axis. By targeting SIRPα directly rather than CD47, the authors of 793 Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity showed that the therapeutic agent avoids the "antigen sink" effect, where widespread CD47 expression on red blood cells absorbs the drug and causes severe anemia.
Genetic Disruption
Beyond monoclonal antibodies, the innate checkpoint system can be permanently altered. As reviewed by Luyao Wang et al. in The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems, CRISPR/Cas9 gene-editing technology allows for the precise knockout of inhibitory receptors directly on macrophages, rendering them permanently insensitive to tumor-mediated suppression.
Eliminating Cancer Stem Cells and Overcoming Resistance
Innate immune checkpoint blockade is particularly vital for targeting cancer stem cells (CSCs), the resilient subpopulation responsible for tumor recurrence and chemotherapy resistance.
Both Yan Zhang et al. in Ovarian cancer stem cells: Critical roles in anti-tumor immunity and Shuo Zhang et al. in Cancer stem cells: a target for overcoming therapeutic resistance and relapse have shown that CSCs heavily overexpress surface proteins like CD47 to construct an immunosuppressive sanctuary. Stripping away this molecular camouflage forces macrophages to destroy the root cells of the tumor, offering a path toward durable clinical remission.
Furthermore, the tumor microenvironment actively drives alternative macrophage suppression pathways. For instance, Han Jiang et al. in PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment discovered that PD-1 expression directly on TAMs suppresses their anti-tumor function via the JAK2-STAT3 signaling pathway, operating independently of its traditional role in T-cells.
Intracellular Innate Checkpoints: The cGAS-STING Axis
The paradigm of innate immune checkpoints extends beyond surface receptors into intracellular sensing pathways. The cGAS-STING pathway acts as an internal alarm system, detecting cytoplasmic tumor DNA and triggering the release of type I interferons to alert the immune system.
Tumors deploy enzymatic and mutational strategies to silence this internal checkpoint:
- Enzymatic Degradation: Songnan Wang et al. in ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer identified ENPP1 as a critical innate checkpoint that hydrolyzes extracellular cGAMP, the essential signaling molecule required to activate STING. Inhibiting ENPP1 prevents this degradation, restoring the immune system's ability to sense the tumor.
- Mutational Interference: Zi Wang et al. in Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53 demonstrated that oncogenic mutations in p53 physically interfere with cGAS-STING machinery, a block that can be reversed using low-dose statins to degrade the mutant proteins.
To maximize therapeutic efficacy, modern approaches combine extracellular phagocytic unmasking with intracellular pathway activation. As shown by Man Li et al. in Radiotherapy-derived engineered stem cell exosomes improve anti-glioma immunotherapy by promoting the formation of tertiary lymphoid structure and improve the release of type I interferon, engineering multi-functional delivery systems (such as stem cell exosomes) to simultaneously activate STING and block CD47 can successfully transform immunologically "cold" microenvironments into highly active zones of tumor clearance.
Key Foundational Work
Ovarian cancer stem cells: Critical roles in anti-tumor immunity (2022) — contributed 2 concept elements to this direction.
859 Combination of HER2 ADC and lemzoparlimab elicits enhanced efficacy in both HER2 high-and low-expressing breast and gastric cancers (2022) — contributed 1 concept elements to this direction.
Tumor-Associated Macrophages: Recent Insights and Therapies (2020) — contributed 1 concept elements to this direction.